Literature DB >> 23627783

Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.

Michael P Bogenschutz1.   

Abstract

Recent developments in the study of classic hallucinogens, combined with a re-appraisal of the older literature, have led to a renewal of interest in possible therapeutic applications for these drugs, notably their application in the treatment of addictions. This article will first provide a brief review of the research literature providing direct and indirect support for the possible therapeutic effects of classic hallucinogens such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of addictions. Having provided a rationale for clinical investigation in this area, we discuss design issues in clinical trials using classic hallucinogens, some of which are unique to this class of drug. We then discuss the current status of this field of research and design considerations in future randomized trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627783     DOI: 10.2174/15733998113099990002

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  12 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

2.  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.

Authors:  Kuglae Kim; Tao Che; Ouliana Panova; Jeffrey F DiBerto; Jiankun Lyu; Brian E Krumm; Daniel Wacker; Michael J Robertson; Alpay B Seven; David E Nichols; Brian K Shoichet; Georgios Skiniotis; Bryan L Roth
Journal:  Cell       Date:  2020-09-17       Impact factor: 41.582

3.  5-HT2A receptor activation normalizes stress-induced dysregulation of GABAergic signaling in the ventral tegmental area.

Authors:  Blake A Kimmey; Alexey Ostroumov; John A Dani
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-05       Impact factor: 11.205

4.  The serotonin 2A receptor agonist TCB-2 attenuates heavy alcohol drinking and alcohol-induced midbrain inhibitory plasticity.

Authors:  Blake A Kimmey; Ruthie E Wittenberg; Alexandra Croicu; Nikita Shadani; Alexey Ostroumov; John A Dani
Journal:  Addict Biol       Date:  2022-03       Impact factor: 4.280

5.  Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.

Authors:  Bruce E Blough; Antonio Landavazo; Ann M Decker; John S Partilla; Michael H Baumann; Richard B Rothman
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

Review 6.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

7.  The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.

Authors:  Elizabeth M Nielson; Darrick G May; Alyssa A Forcehimes; Michael P Bogenschutz
Journal:  Front Pharmacol       Date:  2018-02-21       Impact factor: 5.810

8.  Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT2A receptor activation.

Authors:  April Contreras; Matthew Khumnark; Rochelle M Hines; Dustin J Hines
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

9.  Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism.

Authors:  Marcus W Meinhardt; Simone Pfarr; Grégory Fouquet; Cathrin Rohleder; Manuela L Meinhardt; Janet Barroso-Flores; Rebecca Hoffmann; Jérôme Jeanblanc; Elisabeth Paul; Konstantin Wagner; Anita C Hansson; Georg Köhr; Nils Meier; Oliver von Bohlen Und Halbach; Richard L Bell; Heike Endepols; Bernd Neumaier; Kai Schönig; Dusan Bartsch; Mickaël Naassila; Rainer Spanagel; Wolfgang H Sommer
Journal:  Sci Adv       Date:  2021-11-17       Impact factor: 14.136

Review 10.  Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy.

Authors:  Sascha B Thal; Stephen J Bright; Jason M Sharbanee; Tobias Wenge; Petra M Skeffington
Journal:  Front Psychol       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.